

# Epidemiological factors influencing the development of relapsing and severe *Clostridium difficile* infection

Vojtilová L.<sup>1</sup>, Freibergerová M.<sup>1</sup>, Juráňková J.<sup>2</sup>, Bortlíček Z.<sup>3</sup>, Husa P.<sup>1</sup>

<sup>1</sup>Clinic of Infectious Diseases, Faculty of Medicine, Masaryk University, The University Hospital Brno, Brno, Czech Republic

<sup>2</sup>Department of Clinical Microbiology, The University Hospital Brno, Brno, Czech Republic,

<sup>3</sup>Institute of Biostatistics and Analyses Masaryk University, Brno, Czech Republic

## ABSTRACT

**Introduction:** *Clostridium difficile* infection (CDI) is currently the most frequent cause of nosocomial infectious diarrhea in adults in the developed countries. The goal of the study was to evaluate risk factors for relapsing and severe CDI in a set of patients hospitalized at the Clinic of Infectious Diseases at the University Hospital Brno.

**Materials and methods:** A retrospective analysis of epidemiological, clinical and laboratory data of 281 patients with proved CDI diagnosis hospitalized in the period from 1.1. 2007 to 31.12. 2010.

**Results:** Patient age over 65 is a risk for severe CDI (OR 2.95,  $p < 0.001$ ) and extends hospitalization at the first episode of CDI by about 3.2 days on average. Patients with 2 or more comorbidities ( $p < 0.05$ ) or with a history of recent hospitalization ( $p \leq 0.001$ ) are at risk for both relapsing CDI and severe CDI. The use of proton

pump inhibitors may increase the number of relapses (OR 1.94,  $p < 0.05$ ). If the CDI symptoms appear within 7 days of taking antibiotics, there is a greater risk of relapse (OR 2.32,  $p < 0.05$ ). If the symptoms occur after a longer period, a mild or moderate course of the disease can be expected (OR 0.31,  $p < 0.05$ ).

**Conclusions:** To determine the risk level for development of relapsing or severe CDI, focus on risk factors from the patients' medical history and their clinical and laboratory status is appropriate at the outset of CDI patients' treatment. An early intensive monitoring of vital functions and administration of aggressive treatment can reduce complications, mortality and relapses of CDI.

## KEYWORDS

***Clostridium difficile* infection – risk factors for relapsing CDI – risk factors for severe CDI**

## SOUHRN

**Vojtilová L., Freibergerová M., Juráňková J., Bortlíček Z., Husa P.: Epidemiologické faktory ovlivňující vznik rekurentní a těžké infekce *Clostridium difficile***

**Cíl práce:** Infekce vyvolaná *Clostridium difficile* (CDI) je nyní nejčastější příčinou nosokomiálních infekčních průjmů u dospělých ve vyspělých zemích. Cílem práce bylo popsat rizikové faktory vzniku rekurentního a těžkého průběhu CDI v souboru pacientů hospitalizovaných na Klinice infekčních chorob Fakultní nemocnice Brno.

**Materiál a metody:** Retrospektivní sledování epidemiologických, klinických a laboratorních dat 281 pacientů

s prokázanou diagnózou CDI hospitalizovaných v období od 1.1. 2007 do 31.12. 2010.

**Výsledky:** Věk pacienta nad 65 let je rizikem pro těžký průběh CDI (OR 2.95;  $p < 0.001$ ) a prodlužuje délku hospitalizace při léčbě první episody CDI v průměru o 3,2 dne. Pacient se dvěma a více komorbiditami ( $p < 0,05$ ) nebo s anamnézou předchozí hospitalizace ( $p \leq 0,001$ ) je rizikový jak pro rekurenci onemocnění, tak pro jeho těžký průběh. Užívání blokátorů protonové pumpy může zvyšovat počet rekurencí (OR 1,94;  $p < 0,05$ ). Pokud se příznaky CDI objeví do sedmi dnů od užívání vyvolávajících antibiotik, je větší riziko rekurence onemocnění (OR 2,32;  $p < 0,05$ ). Pokud se však příznaky objeví po delší době, než je týden, lze

## SOUHRNNÁ SDĚLENÍ • PŮVODNÍ PRÁCE • KAZUISTIKY

očekávat lehký nebo středně těžký průběh onemocnění (OR 0,31;  $p < 0,05$ ).

**Závěr:** V úvodu péče o nemocného s CDI je vhodné zaměřit se na rizikové faktory z anamnézy pacienta, jeho klinický a laboratorní status, k určení míry rizika vedoucího k těžkému nebo rekurentnímu průběhu onemocnění. Časné zavedení intenzivního monitorování

životních funkcí a agresivní léčby, může vést ke snížení počtu komplikací, ke snížení mortality a rekurence CDI.

### KLÍČOVÁ SLOVA

infekce *Clostridium difficile* – rizikové faktory  
rekurence CDI – rizikové faktory těžkého průběhu CDI

*Epidemiol. Mikrobiol. Imunol.*, 63, 2014, č. 1, s. 27–35

### INTRODUCTION

Considering the increasing number of reported cases, *Clostridium difficile*-caused infections represent a major health problem in the developed countries. Increasing is not only incidence, but also severity of the disease, mortality, the number of treatment failures and relapses. The infection caused by *C. difficile* is now the leading cause of nosocomial infectious diarrhea in adults in the developed countries [1, 2]. Severity of the disease is alarming especially in geriatric patients, where it leads to increased morbidity and mortality [3]. The rising costs of prevention, diagnosis and treatment associated with this infection represent a significant financial burden to health care.

*C. difficile*, including its toxigenic strains, counts among the common commensals of colonic mucosa in humans and animals. Infection occurs only under certain circumstances. Infection risk factors include intestinal dysmicrobia after antibiotic treatment, patient age over 65, comorbidity, and disorders of the immune system – particularly mucosal immunity [4]. A previous hospitalization poses a significant risk of colonization with hospital *C. difficile* strains. The disease is associated with frequent and repeated relapses, which can lead to exhaustion of the patient and death.

The risk factors of the disease are well described. However, factors determining relapse or severe course of CDI associated with poor patient prognosis are far less known. The focus of this study is to identify the factors leading to relapsing or severe colitis caused by CDI.

### MATERIALS AND METHODS

The retrospective analysis evaluated epidemiological, clinical and laboratory data of patients with proved diagnosis of *C. difficile* infection hospitalized at the Clinic of Infectious Diseases (CID) of The University Hospital (UH) Brno from 1. 1. 2007 to 31. 12. 2010. Data about the patients' age, gender, comorbidities, the number and length of hospitaliza-

lizations at CID, other previous hospitalizations, previous antibiotic use, gastric acid suppressions, corticosteroids and chemotherapies were extracted from the patients' medical records.

The study included inpatients with clinical signs of CDI, who had confirmed toxins A or B in the stool sample. If the sample was negative, and there was a persistent clinical suspicion of CDI, the proof of the toxin in the stool sample was repeated several times with samplings at least one day apart. Cultivated stool samples of all patients were also examined to exclude obligatory intestinal pathogens as alternative cause of infectious diarrhea. Patients diagnosed with CDI at another medical facility and admitted to our clinic only for treatment were excluded from the study, because their laboratory tests were not repeated. Microbiological examinations were conducted at the Department of Clinical Microbiology (DCM) of The University Hospital Brno. In 2007–2009, toxins A and B of *C. difficile* were analyzed by ELISA (Enzyme Linked Immunosorbent Assay) method using the mini-VIDAS set (Bio-Merieux). The immunochromatographic set C.diff Quick chek complete (Techlab) was used in 2010.

CDI relapse was defined as re-appearance of clinical symptoms after an asymptomatic period following an episode of CDI. Each relapse was confirmed by a repeated proof of the CDI toxin in the stool sample and an exclusion of another infectious cause of the diarrhea. The criteria for severe CDI were adopted from the document "Diagnosis and Therapy of *Clostridium difficile* infection: The Czech National Guidelines", published in 2012 [4]. The disease is regarded as severe, if any one of these symptoms presents: fever ( $> 38^{\circ}\text{C}$ ), rigors and chills, haemodynamic instability including signs of septic shock, signs of peritonitis, signs of paralytic ileus, leukocytosis ( $> 15 \times 10^9/\text{L}$ ), marked left shift (band neutrophils  $> 20\%$  of leukocytes), elevated serum creatinine ( $> 50\%$  above the baseline), elevated serum lactate, pseudomembranous colitis (by endoscopy) or distension of large intestine (by imaging).

## SOUHRNNÁ SDĚLENÍ • PŮVODNÍ PRÁCE • KAZUISTIKY

## STATISTICAL EVALUATION


Statistical analysis of data from 281 patients was carried out in two parts. The first analysis evaluated risk factors according to the frequency of CDI relapse, the second one evaluated risk factors according to the severity of CDI. Patients who died during the first hospitalization ( $n = 42$ ,  $n$  – number of patients) as well as patients who died within 30 days of discharge ( $n = 6$ ) were excluded from the CDI relapse evaluation. Therefore, only 233 patients were analyzed. The second analysis – risk factors for severe CDI – included all 281 patients. According to the patients' clinical and laboratory status data during all CDI episodes, a subset of patients with severe course of CDI ( $n = 181$ ) was identified.

Odds ratio (OR) for all parameters was calculated according to univariate logistic regression for relapse or for severe course of the disease. The estimates always included a 95% confidence interval (CI) and a significance level  $p$  (Wald test). The selected level of significance was  $\alpha = 0.05$ . The reference category is always a result related to the complement of patients to the overall 233 patients (the first analysis) or 281 patients (the second analysis), unless stated otherwise. When evaluating the length of the first hospitalization relative to the patient age, statistical significance was assessed non-parametrically using the Mann-Whitney test (MW test).

## RESULTS


In 2007–2010, 281 patients with CDI, confirmed by laboratory tests at the DCM UH Brno, were hospitalized at the Clinic of Infectious Diseases. 73

patients were hospitalized repeatedly, 106 (37.7%) of them were male and 175 (62.3%) were female. Average patient age was 73.2 with a minimum of 19 and a maximum of 99, the median age was 79. Figures 1 and 2 show annual distribution of cases and patient age distribution, respectively. Hospitalization period was 1–55 days. The average length of hospitalization at the first episode of CDI was 16 days (median 14 days). Comparison of age groups  $\leq 65$  and over 65 has shown a statistically significant difference in the length of the first hospitalization (the result of M-W test = 0.003). The length of the first hospitalization in the group of younger patients was 13.5 days on average (median 12), but in the group of elderly patients, the



**Fig. 1** The number of hospitalized CDI patients in years 2007–2010 divided into age subsets

**Graf. 1** Počet hospitalizovaných pacientů s CDI v jednotlivých letech s věkovým rozdělením



**Fig. 2** Distribution of CDI patients by age

**Graf. 2** Věkové rozložení pacientů s CDI

## SOUHRNNÁ SDĚLENÍ • PŮVODNÍ PRÁCE • KAZUISTIKY

average was 16.7 days (median 15). Patients older than 65 stayed in the hospital by 3.2 days longer on average.

### 1. The risk factors for relapsing CDI

In the first analysis of data from 233 patients, 87 (37.3%) patients had relapsing disease and 146 (62.7%) patients had only a single episode of CDI. Out of the 174 patients in the age group over 65, 70 patients (40.2%) relapsed,  $p = 0.119$ . Neither age over 65, nor gender was a risk for relapse according to our analysis. Data about the following comorbidities were collected from the patients' medical history: ischemic heart disease, diabetes mellitus, cerebrovascular diseases, chronic renal failure, immobility, chronic obstructive pulmonary disease and oncological diseases. A coincidence of 2

or more comorbidities represented a significantly higher risk of relapse,  $p = 0.013$  (Table 1).

A hospitalization within 4 weeks before the onset of CDI was a significant risk factor. There were 149 previously hospitalized patients, of whom 71 had relapsed (47.7%),  $p < 0.001$ . Other previous institutionalizations (a stay in a retirement home or a rest home) did not represent a risk of relapsing CDI (see Table 1).

A previous antibiotic treatment within 60 days before the CDI diagnosis was documented in 207 patients, 82 of them received 2 or more antibiotics. Neither the type of antibiotics, nor their combination factored in the relapse. The interval between the onset of CDI symptoms and the antibiotic treatment was also evaluated. The patients were more prone to relapse if their symptoms of

**Table 1.** Evaluation of CDI relapse relative to the patients' medical history

**Tabulka 1.** Vyhodnocení rekurence CDI vzhledem k anamnestickým údajům pacientů

	Total, n	Patients with relapse, n (%)	Odds ratio (95% IS)	P-value
Total number of patients	233	87 (37.3)	-	-
Age at 1st hospitalization				
≤ 65 years	59	17 (28.8)	reference category	-
> 65 years	174	70 (40.2)	1.66 (0.88-3.15)	0.119
Gender				
Male	87	31 (35.6)	reference category	-
Female	146	56 (38.4)	1.12 (0.65-1.95)	0.678
Comorbidities				
Ischemic heart disease	107	44 (41.1)	1.35 (0.79-2.30)	0.272
Diabetes mellitus	57	20 (35.1)	0.88 (0.47-1.64)	0.686
Cerebrovascular disease	53	24 (45.3)	1.54 (0.83-2.86)	0.175
Chronic renal failure	50	15 (30.0)	0.66 (0.34-1.30)	0.228
Immobility	48	22 (45.8)	1.56 (0.82-2.97)	0.174
Chronic obstructive pulmonary disease	33	14 (42.4)	1.28 (0.61-2.71)	0.515
Oncological disease	29	14 (48.3)	1.67 (0.77-3.66)	0.196
Number of comorbidities				
0 or 1	105	30 (28.6)	reference category	-
2 or more	128	57 (44.5)	2.01 (1.16-3.47)	0.013
Previous hospitalization				
0-4 weeks	149	71 (47.7)	3.87 (2.06-7.28)	< 0.001
Institutionalization				
No	209	76 (36.4)	reference category	-
Yes	24	11 (45.8)	1.48 (0.63-3.47)	0.366

## SOUHRNNÁ SDĚLENÍ • PŮVODNÍ PRÁCE • KAZUISTIKY

**Table 2.** Evaluation of CDI relapse relative to history of antibiotics administration, gastric acid suppression and the use of immunosuppressive drugs**Tabulka 2.** Vyhodnocení rekurence CDI vzhledem k předchozímu užívání antibiotik, antiulcerózní a imunosupresivní terapie

	Total, n	Patients with relapse, n (%)	Odds ratio (95% IS)	P-value
Total number of patients	233	87 (37.3)	-	-
Previous antibiotics				
No	21	6 (28.6)	reference category	-
Yes	207	79 (38.2)	1.54 (0.57-4.14)	0.389
Number of antibiotics				
0	21	6 (28.6)	reference category	-
1	101	45 (44.6)	2.01 (0.72-5.60)	0.182
2 or more	82	27 (32.9)	1.23 (0.43-3.52)	0.703
Time of the CDI symptoms onset relative to the administration of antibiotics				
Symptoms during treatment	89	24 (27.0)	reference category	-
Within 7 days after treatment	39	18 (46.2)	2.32 (1.06-5.09)	0.035
More than 7 days after treatment	16	8 (50.0)	2.71 (0.91-8.02)	0.072
Other therapy				
Proton pump inhibitors	97	45 (46.4)	1.94 (1.13-3.32)	0.016
H2 receptor antagonists	7	2 (28.6)	0.66 (0.13-3.50)	0.629
Chemotherapy	4	2 (50.0)	1.69 (0.23-12.25)	0.601
Corticosteroids	21	8 (38.1)	1.04 (0.41-2.61)	0.940

diarrhea occurred during the first week after the end of antibiotic treatment,  $p = 0.035$  (Table 2). Previous use of antiulcer drugs and immunosuppressive drugs was also monitored. Out of 97 patients of the entire set, who had a history of proton pump inhibitors use, 45 patients (46.4%) had relapsed,  $p = 0.016$ . Consequently, the use of proton pump inhibitors increased the risk of relapse. The previous use of histamine H2 receptor antagonists, treatments with systemic corticosteroids (dose  $\geq 5$  mg prednisone) at the time of CDI, or the use of chemotherapy in the last 60 days did not affect the emergence of the CDI relapse (see Table 2).

## 2. The risk factors for severe CDI

Severe CDI during any episode of the disease was observed in 181 (64.4%) of all 281 patients, while the remaining 100 (35.6%) patients had a mild or moderate course of CDI.

Patient age over 65 was definitely a risk factor for severe CDI. Out of 216 patients over 65 years old, 152 (70.4%) had severe CDI,  $p = 0.001$ . Gender was not in correlation with the severity of the disease. Among the observed comorbidities, a group of patients with a history of ischemic heart disease and

chronic renal failure were at risk for severe CDI, as were also patients with 2 or more comorbidities (Table 3).

Patients, previously hospitalized 4 weeks before the onset of CDI, had more likely a severe course of the disease. Out of the 188 previously hospitalized patients, 134 patients had severe CDI (71.3%),  $p = 0.001$ . Previous institutionalization was not a risk of severe CDI (see Table 3).

Previous use of antibiotics singly or in a combination did not pose a risk of severe CDI development. The patients with CDI symptoms onset more than 7 days after antibiotic treatment were statistically less affected by severe CDI than patients who had symptoms during the antibiotic treatment or within one week since. The use of antiulcer drugs, treatment with systemic corticosteroids at the time of CDI, or the use of chemotherapy in the last 60 days did not affect the severity of CDI (Table 4).

## DISCUSSION

Since 2007, a significant increase in the number of CDI cases was noted at our clinic. Until then, it was only individual cases. This trend follows the

## SOUHRNNÁ SDĚLENÍ • PŮVODNÍ PRÁCE • KAZUISTIKY

**Table 3.** Evaluation of severe CDI relative to the patients' medical history**Tabulka 3.** Vyhodnocení těžkého průběhu CDI vzhledem k anamnestickým údajům pacientů

	Total, n	Patients with relapse, n (%)	Odds ratio (95% IS)	P-value
Total number of patients	281	181 (64.4)	-	-
Age at 1st hospitalization				
≤ 65 years	65	29 (44.6)	reference category	-
> 65 years	216	152 (70.4)	2.95 (1.67–5.21)	<0.001
Gender				
Male	106	70 (66.0)	reference category	-
Female	175	111 (63.4)	0.89 (0.54–1.48)	0.658
Comorbidities				
Ischemic heart disease	130	94 (72.3)	1.92 (1.16–3.17)	0.011
Diabetes mellitus	67	46 (68.7)	1.28 (0.71–2.30)	0.406
Cerebrovascular disease	59	39 (66.1)	1.10 (0.60–2.01)	0.761
Chronic renal failure	64	52 (81.3)	2.96 (1.49–5.86)	0.002
Immobility	58	42 (72.4)	1.59 (0.84–3.00)	0.155
Chronic obstructive pulmonary disease	40	27 (67.5)	1.17 (0.58–2.39)	0.660
Oncological disease	38	29 (76.3)	1.93 (0.87–4.26)	0.104
Number of comorbidities				
0 or 1	131	73 (55.7)	reference category	-
2 or more	150	108 (72.0)	2.04 (1.24–3.35)	0.005
Previous hospitalization				
0–4 weeks	188	134 (71.3)	2.43 (1.45–4.06)	0.001
Institutionalization				
No	250	160 (64)	reference category	-
Yes	31	21 (67.7)	1.18 (0.53–2.62)	0.682

incidence of CDI reported in the Czech Republic. According to the Epidat database of The National Institute of Public Health in the Czech Republic, 303 cases of CDI were reported in 2008, 1,552 cases in 2011, and a total of 2,241 cases in 2012 [5]. By comparison, the study of authors Polívková et al. included 82 patients with CDI for the period from 1. 1. 2008 to 30. 6. 2010 [6]. However, the increased number of reported CDI cases in the Czech Republic in recent years is partly influenced by the implementation of better diagnostic methods and improved quality of reporting.

The average length of the first hospitalization of CDI patients was 16 days, almost twice longer than the average length of stay of all patients admitted to CID in 2007–2010 (8.3 days). In addition, the

average length of the first hospitalization for the treatment of CDI in patients older than 65 was by 3.2 days longer than in younger patients. Aside from severe course of CDI, it might be caused by a greater frequency and severity of comorbidities at the older age.

Any course of CDI in the patients over 65 is considered serious, even without clinical signs of severe colitis; this was confirmed in our evaluation, too. Age over 65 did not represent a significant risk for CDI relapse. There were 1.5 times more women than men in our patient set, but the patients' gender was not correlated to the severity or relapse of CDI. Many studies did not find a relationship between gender and severity of CDI, although one prospective study suggests a link between the male

## SOUHRNNÁ SDĚLENÍ • PŮVODNÍ PRÁCE • KAZUISTIKY

**Table 4.** Evaluation of severe CDI relative to history of antibiotics administration, gastric acid suppression and the use of immunosuppressive drugs**Tabulka 4.** Vyhodnocení těžkého průběhu CDI vzhledem k předchozímu užívání antibiotik, antiulcerózní a imunosupresivní terapie

	Total, n	Patients with relapse, n (%)	Odds ratio (95% IS)	P-value
Total number of patients	281	181 (64.4)	-	-
Previous antibiotics				
No	23	14 (60.9)	reference category	-
Yes	253	165 (65.2)	1.21 (0.50–2.90)	0.676
Number of antibiotics				
0	23	14 (60.9)	reference category	-
1	123	77 (62.6)	1.08 (0.43–2.68)	0.875
2 or more	100	72 (72.0)	1.65 (0.64–4.25)	0.297
Time of the CDI symptoms onset in a relation to the administration of antibiotics				
Symptoms during treatment	104	70 (67.3)	reference category	-
Within 7 days after treatment	47	28 (59.6)	0.72 (0.35–1.46)	0.357
More than 7 days after treatment	18	7 (38.9)	0.31 (0.11–0.87)	0.026
Other therapy				
Proton pump inhibitors	117	83 (70.9)	1.64 (0.99–2.73)	0.054
H2 receptor antagonists	10	7 (70.0)	1.30 (0.33–5.15)	0.708
Chemotherapy	4	3 (75.0)	1.67 (0.17–16.26)	0.659
Corticosteroids	25	18 (72.0)	1.47 (0.59–3.64)	0.409

gender and severe course of CDI. The study did not prove a correlation between ethnicity and severity of the disease [7]. Pépin's retrospective study of 2007, including 1,616 CDI inpatients at a Canadian tertiary care hospital, described the following risk factors for severe CDI: age over 65, male gender, immunosuppression, nosocomial infections, enteral nutritions, short duration of diarrhea, fever, leukocytosis and increased creatinine [8].

The number of comorbidities is correlated to the patient's age; therefore the combination of 2 or more monitored comorbidities presents a risk of both relapsing and severe CDI. Our study did not confirm the expected impact of patient's long-term immobility on relapse or severity of CDI. Some studies have reported pre-existing renal insufficiency or chronic pulmonary disease as a risk factor for increased mortality. A correlation between severe CDI and a history of malignancy has also been suggested [9, 10]. Interestingly, despite the widely accepted fact about increased susceptibility of diabetes mellitus patients to various infections, none of the studies has demonstrated a link between diabetes mellitus and severity of CDI [9].

Publications classify CDI as healthcare facility onset CDI (begins 48 hours after admission to the hospital), healthcare facility-associated community onset CDI (up to 4 weeks after hospitalization) or community associated CDI (symptoms begin more than 12 weeks after previous hospitalization). The period between 4–12 weeks after hospitalization is referred to as indeterminate [11]. Previous hospitalization within 4 weeks before the onset of CDI represents a significant risk factor for relapse and severity of CDI in our patient set. According to our results, a stay in a retirement home without prior hospitalization is not a risk for development of CDI. Asymptomatic faecal carriage of *C. difficile* was reported in 10% of residents in an Irish continuing care institution for the elderly, 7% of them were toxin positive [12]. There is no information available about *C. difficile* carriage in the Czech Republic. The use of antibiotics is considered the most important risk factor for intestinal colonization with strains of *C. difficile*. Lincosamides, aminopenicillins, cephalosporins and quinolones represent the highest risk levels. Aminoglycosides, co-trimoxazole, penicillin, carbapenems and tetracyclines

## SOUHRNNÁ SDĚLENÍ • PŮVODNÍ PRÁCE • KAZUISTIKY

are considered relatively safe [13–15]. According to our results, the use of any specific class of antibiotics cannot be correlated with the risk of relapse or severe CDI, although the use of quinolones was described as a risk factor for relapsing CDI in a smaller patient set in the USA [16].

Suppressed acidity of gastric secretion predisposes to a variety of intestinal infections. Some studies indicate the use of proton pump inhibitors as a risk factor for CDI, but others have not confirmed this [17–20]. Howell et al. documented an increased risk of nosocomial infection of *C. difficile* depending on the pharmacological suppression of gastric acid secretion [18]. A connection between pharmacological suppression of gastric acid secretion and severity of CDI has not been demonstrated yet [21, 22]. Another study comprising 125 patients identified the use of proton pump inhibitors as well as the age over 65 and a low serum albumin (< 25 g/L) as significant risk factors for CDI relapse [23]. The relationship between the use of proton pump inhibitors and the risk of relapse, demonstrated by our study, indicates a reinfection with *C. difficile* rather than a relapse of previous disease. CDI patients contaminate the hospital environment with spores contained in the stool, which can be a source of reinfection of predisposed persons. It is important to realize that a failure of antibiotic treatment due to the resistance of *C. difficile* is not the cause of these recurrences [4].

Treatment with systemic corticosteroids at the time of CDI or the use of chemotherapy in the last 60 days did not influence relapses or disease severity in our patient set. Our results do not correspond with the described effect of immunosuppression as a risk factor for severe CDI [8], nor with the results of another study, which demonstrated a significant 2.1-fold increase in 30-day mortality in CDI patients who received corticosteroids for at least 15 days before the CDI diagnosis [24].

### CONCLUSIONS

Retrospective analysis of clinical and epidemiological data of patients hospitalized at CID with a proved diagnosis of *C. difficile* infection in 2007–2010 leads to the following key conclusions:

1. Patient age over 65 is a risk factor of severe CDI (OR 2.95,  $p < 0.001$ ) and leads to extension of hospitalization at the first episode of CDI by about 3.2 days on average.
2. Patients with 2 or more comorbidities ( $p \leq 0.05$ ) or with a history of recent hospitalization ( $p \leq 0.001$ ) are at risk for relapsing CDI and also severe CDI.
3. The use of proton pump inhibitors may increase the number of relapses (OR 1.94,  $p < 0.05$ ),

probably because of reinfection with spores of *C. difficile*.

4. If CDI symptoms appear within 7 days of taking antibiotics, there is a greater risk of relapse (OR 2.32,  $p < 0.05$ ). If the symptoms occur after a longer period such as one week, a mild or moderate course of the disease can be expected (OR 0.31,  $p < 0.05$ ).

At the beginning of CDI patients' treatment, it is appropriate to focus on risk factors known from patients' medical history and their clinical and laboratory status to assess risk of relapsing or severe disease. Early intensive monitoring of vital functions and administration of aggressive treatment can reduce complications, mortality and relapses of CDI.

### References

1. Archbald-Pannone L, Sevilleja JE, Buerrant R. Diarrhea, *Clostridium difficile*, and Intestinal Inflammation in Residents of a Long-Term Care Facility. *J Am Med Dir Assoc*, 2010;11:263–267.
2. Markis AT, Gelone S. *Clostridium difficile* in the long-term care setting. *J Am Med Dir Assoc*, 2007;8:290–299.
3. Bielaková K, Weber P, Matějkovská-Kubešová H, et al. The disease caused by *Clostridium difficile* in geriatric patients. *Čas Lék Čes*, 2011;150:334–338.
4. Beneš J, Husa P, Nyč O. Doporučený postup diagnostiky a léčby kolitidy vyvolané *Clostridium difficile*. *Klin Mikrobiol Inf Lek*, 2012;18(5):160–167.
5. Státní zdravotní ústav, databáze Epidat. Dostupné na [www.szu.cz](http://www.szu.cz).
6. Polívková S, Sýkorová B, Džupová O, Reisingerová M, Beneš J. Výskyt a charakter infekcí vyvolaných *Clostridium difficile* u pacientů s průjmovým onemocněním v pražské fakultní nemocnici. *Klin Mikrobiol Inf Lek*, 2010;16(6):206–210.
7. Arora V, Kachroo S, Ghantooji SS, Dupont HL, Garey KW. High Horn's index score predicts poor outcomes in patients with *Clostridium difficile* infection. *J Hosp Infect*, 2011;79(1):23–26.
8. Pépin J, Valiquette L, Gagnon S, Routier S, Brazeau I. Outcomes of *Clostridium difficile*-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. *Am J Gastroenterol*, 2007;102:2781–2788.
9. Potter VA, Aravindhan A. Identifying patients at risk of severe *Clostridium difficile*-associated disease. *British Journal of Hospital Medicine*, 2012;73(5):265–270.
10. Lungulescu OA, Cao W, Gatskevich E, Tlhabano L, Stratidis JG. CSI: a severity index for *Clostridium difficile* infection at the time of admission. *J Hosp Infect*, 2011;79(2):151–154.
11. Cohen SH, Gerding DN, Johnson S et al. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). *Infect Control Hosp Epidemiol*, 2010;31(5):431–455.
12. Ryan C, Murphy C, Twomey C et al. Asymptomatic carriage of *Clostridium difficile* in an Irish continuing care institution for elderly: prevalence and characteristics. *Ir J Med Sci*, 2010;179(2):245–250.

## SOUHRNNÁ SDĚLENÍ • PŮVODNÍ PRÁCE • KAZUISTIKY

13. Owens RC. *Clostridium difficile* – associated disease. Changing epidemiology and implications for management. *Drugs*, 2007;67(4):487–503.

14. Beneš J, Sýkorová B. Kolitida vyvolaná *Clostridium difficile*. Zpráva z kongresu ICAAC 2006. *Klin Mikrobiol Inf Lek*, 2006;12(6):247–251.

15. Hubert B, Loo VG, Bourgault AM, et al. A portrait of the geographic dissemination of the *Clostridium difficile* North American pulsed-field type 1 strain and the epidemiology of *C. difficile*-associated disease in Québec. *CID*, 2007;44:238–244.

16. Cadena J, Thompson GR, Patterson JE, et al. Clinical predictors and risk factors for relapsing *Clostridium difficile* infection. *Am J Med Sci*, 2010;339(4):350–355.

17. Cloud J, Kelly CP. Update on *Clostridium difficile* associated disease. *Current Opinion in Gastroenterology*, 2007;23(1):4–7.

18. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial *Clostridium difficile* infection. *Arch Intern Med*, 2010;170(9):784–790.

19. DuPont HL, Garey K, Caeiro JP, Jiang ZD. New advances in *Clostridium difficile* infection: changing epidemiology, diagnosis, treatment and control. *Curr Opin Infect Dis*, 2008;21:500–507.

20. Dubberke ER, Reske KA, Yan Y, et al. *Clostridium difficile* – associated disease in a setting of endemicity: Identification of novel risk factors. *CID*, 2007;45:1543–1549.

21. Moshkowitz M, Ben-Paruch E, Kline Z, et al. Risk factors for severity and relapse of pseudomembranous colitis in an elderly population. *Colorectal Dis*, 2007;9(2):173–177.

22. Bishara J, Peled N, Pitlik S, Samra Z. Mortality of patients with antibiotic-associated diarrhoea: the impact of *Clostridium difficile*. *J Hosp Infect*, 2008;68(4):308–314.

23. Kim JW, Lee KL, Jeong JB, et al. Proton pump inhibitors as a risk factor for recurrence of *Clostridium difficile*-associated diarrhea. *World J Gastroenterol*, 2010;16(28):3573–3577.

24. Das R, Feuerstadt P, Brandt LJ. Glucocorticoids Are Associated With Increased Risk of Short-Term Mortality in Hospitalized Patients with *Clostridium difficile*-Associated Disease. *Am J Gastroenterol*, 2010;105:2040–2049.

Do redakce došlo dne 29. 7. 2013.

Adresa pro korespondenci:

**MUDr. Lenka Vojtilová, Ph.D.**  
Jánošíkova 36  
643 00 Brno  
e-mail: lvojtilova@fnbrno.cz

**Infanrix™ hexa**

MŮŽETE SE SPOLEHNOUT

Podobně jako u jiných vakcín, nemusí být u všech očkovaných jedinců vyvolána ochranná imunitní odpověď. Bezpečnost a účinnost u dětí starších 36 měsíců nebyla stanovena.

GlaxoSmithKline s.r.o., Hvězdova 1734/2c, 140 00 Praha 4, Česká republika, tel.: 222 001 111, fax: 222 001 444; e-mail: cz.info@gsk.com; www.gsk.cz

Infanrix hexa™ je ochranná známka skupiny firem GlaxoSmithKline.

© 2013 GlaxoSmithKline. Všechna práva vyhrazena.



Asociace inovativního farmaceutického průmyslu

CZ/INF/003/14

**ZKRÁCENÝ SOUHRN ÚDAJŮ O PŘÍPRAVKU: NÁZEV PŘÍPRAVKU:** Infanrix hexa, prášek a suspenze pro přípravu injekční suspenze v předplněné injekční stříkačce. Vakcína proti difterii (D), tetanu (T), perltis (acekulární komponenta) (Pa), hepatitidě B (DNA) (HBV), poliometylidit (inaktivovaná) (IPV) a konjugovaná vakcína proti *Haemophilus influenzae* typu b (Hib). (adsorbovaná). **Kvalitativní a kvantitativní složení:** Po rekonstituaci jedna dávka (0,5 ml) obsahuje: Diphtheria anatoxinum ne méně než 30 mezinárodních jednotek (IU), tetani anatoxinum ne méně než 40 mezinárodních jednotek (IU), pertussis anatoxinum 25 mikrogramů, haemagglutininum filamentosum 25 mikrogramů, pertactinum 8 mikrogramů, antigenum tegininis hepatitidis B 10 mikrogramů, virus poliomyleitis (inaktivovaný) typus 1 (kmen Mahoney) 40 D jednotek antigenu, typus 2 (kmen MEF-1) 8 D jednotek antigenu, typus 3 (kmen Saukett) 32 D jednotek antigenu, *Haemophilus influenzae* typus b polysaccharidum 10 mikrogramů (polyribosyrbitolu phosphas) conjugata cum tetani anatoxinum jako nosným proteinem přibližně 25 mikrogramů, pomocná látky: hydroxid hliník, hydratovaný (Al(OH))<sub>3</sub> 0,5 mikrogramu Al<sup>3+</sup>, fosforečnan hliníku (AlPO<sub>4</sub>) 0,32 mikrogramu Al<sup>3+</sup>, bezváhu laktóza, chlorid sodný (NaCl), kultivační médium M 199 obsahující flavén aminokyseliny, minerální soli a vitaminy, voda na injekci. **Indikace:** Infanrix hexa je určen pro základní očkování a přeocrování dětí proti difterii, tetanu, perltis, hepatitidě B, poliometylidit a onemocněním způsobeným *Haemophilus influenzae* typu b. **Dávkování a způsob podání:** Základní očkovací schéma spočívá v podání iří 0,5 ml dávky (například ve 2., 3., 4. měsíci; ve 3., 4., 5. měsíci a ve 2., 4., 6. měsíci) nebo dvou dávek (například ve 3. a 5. měsíci). Mezi jednotlivými dávkami musí být interval nejméně 1 měsíc. Jestliže je při narození podána první dávka vakcíny proti hepatitidě B, může být od věku 6 týdnů k podání dalších dávek vakcíny proti hepatitidě B použita vakcína Infanrix hexa. Pokud se druhá dávka vakcíny proti hepatitidě B podává před dosažením tohoto věku, je nutné použít monovalentní vakcínu proti hepatitidě B. Po očkování 2 dávkami vakcíny Infanrix hexa (například ve 2., 3., 4. měsíci; ve 3., 4., 5. měsíci a ve 2., 4., 6. měsíci) se musí podat poslední dávka nejméně 6 měsíců po podání poslední dávky základního očkování. Upřednostňuje se podání před 18. měsícem věku dítěte. Bezpečnost a účinnost vakcíny Infanrix hexa u dětí starších 36 měsíců nebyla stanovena. Infanrix hexa je určen k hluboké intramuskulární aplikaci. Další dávky je vhodné podávat vždy do opačné končetiny, než byla podána předchozí dávka. **Kontraindikace:** Přeťitěllost na léčivé látky nebo na jakékoli pomocné látky nebo na neonycoin a polymyxin. Přeťitěllost po předchozí aplikaci vakcíny proti difterii, tetanu, perltis, hepatitidě B, poliometylidit nebo Hib. Infanrix hexa je kontraindikován u dětí, u nichž se do sedmi dnů po předchozí očkování vakcíny obsahující pertusovou složku vyskytla encéfalitida neznaměřitelné etiologie. V takových případech se musí očkování proti perlti přerušit a dále se očkuje jen vakcíny proti záštku-tetanu, hepatitidě B, poliometylidit a Hib. Podobně jako u jiných vakcín i aplikace vakcíny Infanrix hexa musí být odlišena u osob trpících významným akutním horečnatým onemocněním. Přitomnost slabé infekce však není povážována za kontraindikaci. **Zvláštní upozornění:** Jestliže dojde v časové souvislosti s aplikací vakcíny obsahující pertusovou složku k některé z dalek popsaných reakcí, je nutné rádově vžádat podání dalších dávek vakcín, které pertusovou složku obsahují. Teplota ≥ 40,0 °C během 48 hodin po očkování s neprakroužnou jinou souvislostí, kolaps nebo šokový stav (hypotonicko-hyporeaktivní episode) během 48 hodin po očkování, trvalý neutříšťový plášť trvající > 40,0 °C během 48 hodin po očkování s neprakroužnou jinou souvislostí, výskyt výdatové kaše, však očekávaný přípon imunizace převážně možná rizika. Podobně jako u jiného očkování by se měl pečlivě vžádat prospekt a riziko imunizace vakcíny Infanrix hexa nebo její odklad u kojenců nebo u dětí trpících nástupem nové ataky nebo progresí závažné neurologické poruchy. Stejně jako u jiných injekčních vakcín musí být i po aplikaci této vakcíny pro případ rozvoje anafylaktického šoku okamžitě k dispozici odpovídající lekařská pomoc a důležit. Nemocný s trombocytopenií a s poruchami srážlivosti krv musí být vakcína Infanrix hexa aplikována se zvýšenou opatrností, neboť po intramuskulárním podání může dojít k krvácení. Infanrix hexa nesmí být v žádném případě aplikován intravaskulárně nebo intradermálně. Podobně jako u jiných vakcín, nemusí být všechny očkovány anamnéze dítěte, výskyt febrilních křečí nebo SIDS (syndrom náhlého úmrtí dítěte) v rodině anamnéze není kontraindikací pro použití vakcíny Infanrix hexa. Očkování jedince, u nichž se v anamnéze febrilní křeč vyskytuje, je třeba pečlivě sledovat, protože se tyto nežádoucí účinky mohou během 2 až 3 dnů po vakcinaci objevit. Infekce HIV nepředstavuje kontraindikaci pro vakcinaci. Předčasně narozený dítě je možné na základě omezených údajů ziskaných od 169 předčasně narozených dětí vakcíny Infanrix hexa podat. Nicméně, byla zaznamenána nižší imunitní odpověď a úroveň klinické protekce není známa. Možné riziko apnoe a nutrost monitorování dýchání po dobu 48 – 72 hodin by mělo vžádat při podávání dávek základního očkování velmi předčasně narozených dětem (narozené v ≤ 28. týdnu těhotenství) a zvláště těm, v jejichž případě anamnéze byla respirační nezralost. Proteže prospekt očkování je u této skupiny dětí vysoký, neměla by se vakcinace odmítnout ani odložovat. **Interakce s jinými léčivými přípravky a jiné formy interakce:** O současném podání vakcíny Infanrix hexa a kombinované vakcíny proti spalničkám, příručním a zářidlím nejsou k dispozici dostatečně údaje týkající se účinnosti a bezpečnosti, které by umožnily stanovit nějaká doporučení. Údaje vycházejí ze současného podávání Infanrix hexa a Prevenar (pneumoková sacharidová konjugovaná vakcína, adsorbovaná) neprakroužná ačelulární pertusovou složku je po přeocrování pravděpodobnější výskyt otoku ve srovnání s dlešími očkovánými celobuněčnými vakcínami. Tyto reakce odezněly za 4 dny. **Inkompatibilita:** Infanrix hexa nesmí být misen s žádnými dalšími lečivými přípravky. **Doba použitelnosti:** 3 roky. **Zvláštní opatření pro uchovávání:** Uchovávajte v chladničce (2 °C – 8 °C). Chraňte před mrazem. Uchovávajte v původním obalu, aby byl přípravek chráněn před světlem. Po rekonstituaci se doporučuje použít vakcínu ihned. **Držitel rozhodnutí o registraci:** GlaxoSmithKline Biologicals s. a. Rue de l' Institut 89, B-1330 Rovensk, Belgia. **Registracní číslo:** EU/1/00/152/001-008. **Datum první registrace/prodloužení registrace:** 23. 10. 2000/23. 10. 2010. **Datum revize textu:** 6. 9. 2013. Lék je vázán na lekárský předpis. Přípravek je hrazen z prostředků veřejného zdravotního pojištění. Před předpisy líku se prosím seznámit s úplnou informací o přípravku, kterou najdete v Souhrnu údajů o přípravku i na www.gsk.com nebo se obrátit na společnost GlaxoSmithKline, s.r.o., Hvězdova 1734/2c, 140 00 Praha 4, e-mail: cz.info@gsk.com; www.gsk.cz. Případné nežádoucí účinky prosím hlásat také na cz.safety@gsk.com. Verze SPC platná ke dni 26. 2. 2014.